Minor/Major Congenital Malformations and Neurodevelopmental Outcomes in Children Prenatally Exposed to Levetiracetam, Lamotrigine, and Carbamazepine Monotherapy

dc.authorscopusidGülce Alev Savtak / 55992681700
dc.contributor.authorErtürk Çetin, Özdem
dc.contributor.authorAlgedik, Pınar
dc.contributor.authorAkyüz, Gülcan
dc.contributor.authorSürmeli, Reyhan
dc.contributor.authorZanapalıoğlu, Ümit
dc.contributor.authorAlev Savtak, Gülce
dc.contributor.authorGüven, Şirin
dc.date.accessioned2025-04-18T10:01:24Z
dc.date.available2025-04-18T10:01:24Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Lisansüstü Eğitim Enstitüsü, Sağlık Bilimleri, Dil ve Konuşma Terapisi Programı
dc.description.abstractObjectives The relationship of older antiseizure drugs with congenital malformations has been known for many years. Studies are mostly limited to major malformations and few studies have investigated minor malformations. In recent years, the long-term cognitive and behavioral effects of these drugs have also come to the fore. The aim of our study was to evaluate the incidence of major and minor congenital malformations and neurodevelopmental outcomes in children prenatally exposed to levetiracetam (LEV), lamotrigine (LTG), and carbamazepine (CBZ) monotherapy. Methods This was a prospective observational study conducted in two university hospital epilepsy centers. It included 32 pregnant women who were continuously treated with LEV, LTG, or CBZ from conception throughout pregnancy. Children were followed up from birth until 18 months. Neurodevelopmental outcomes were evaluated with the Ages and Stages Questionnaire and Denver Developmental Screening Test. Results Eighteen of the patients were on LEV, 10 were on LTG, and 4 were on CBZ. Diaphragmatic hernia was detected in a child. At least one minor anomaly was observed in 58.1% of the patients. More than 80% of children were normal in the Ages and Stages Questionnaire. Conclusions The risk of major congenital malformations is lower with newer antiseizure drugs. We found a high incidence of minor ones. However, because the population prevalence of minor malformations is also variable, more studies are needed to confirm the results. Neurodevelopmental outcomes were favorable with LTG and LEV and slightly unfavorable with CBZ. Longer-term follow-up with large groups of children is required to reach more reliable results. © Wolters Kluwer Health, Inc. All rights reserved.
dc.identifier.citationÇetin, Ö. E., Algedik, P., Akyüz, G., Sürmeli, R., Zanapalıoğlu, Ü., Saltak, G. A., & Güven, Ş. Minor/Major Congenital Malformations and Neurodevelopmental Outcomes in Children Prenatally Exposed to Levetiracetam, Lamotrigine, and Carbamazepine Monotherapy. Clinical Neuropharmacology, 10-1097.
dc.identifier.doi10.1097/WNF.0000000000000600
dc.identifier.issn03625664
dc.identifier.pmid38976241
dc.identifier.scopus2-s2.0-85198526770
dc.identifier.scopusqualityQ3
dc.identifier.urihttp://dx.doi.org/10.1097/WNF.0000000000000600
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6917
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSavtak, Gülce Alev
dc.institutionauthoridGülce Alev Savtak / 0000-0002-8808-8144
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofClinical Neuropharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMinor Congenital Malformations
dc.subjectMajor Congenital Malformations
dc.subjectNeurodevelopment
dc.subjectLevetiracetam
dc.subjectLamotrigine
dc.subjectCarbamazepine
dc.titleMinor/Major Congenital Malformations and Neurodevelopmental Outcomes in Children Prenatally Exposed to Levetiracetam, Lamotrigine, and Carbamazepine Monotherapy
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: